BPC-157 vs TB-500
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 4 cited sources
BPC-157 and TB-500 are the two most popular “healing” peptides, and they’re often used together. They come from different sources and are thought to work through different mechanisms — which is the main argument for stacking them — but both share the same core limitation: almost all of the research is in animals.
At a glance
| BPC-157 | TB-500 | BPC-157/TB-500 | |
|---|---|---|---|
| Origin | Fragment of a protein in gastric juice | Synthetic fragment of thymosin beta-4 | Combination of both |
| Proposed mechanism | Angiogenesis, growth-factor signaling | Actin regulation, cell migration | Both pathways |
| Typical reference dose | 250–500 mcg, Daily or ED | 2.5–5 mg, 2×/week loading, then weekly | 500 mcg, Daily |
| Regulatory status | Research | Research | Research |
| Research volume | 2.0/5 | 1.5/5 | 2.0/5 |
| Human / animal studies | 3 / 60 | 2 / 35 | 3 / 45 |
Research volume reflects how much research exists, not effectiveness. Doses are commonly reported reference protocols, not recommendations.
How they differ
BPC-157 is a 15-amino-acid peptide derived from a protective protein found in stomach juice. In rodent studies it has been reported to speed healing of tendons, ligaments, muscle, and the gut lining, with proposed mechanisms involving new blood vessel formation and growth-factor receptor expression in tendon cells. TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein that regulates actin — part of the cell’s internal scaffolding — and helps cells migrate into damaged tissue.
Because BPC-157 is associated with local blood supply and TB-500 with cell migration, users stack them on the theory that they cover complementary parts of the repair process. That theory is plausible but has not been tested in human trials.
What the evidence actually shows
A 2025 systematic review of BPC-157 in orthopaedic sports medicine found the evidence base was overwhelmingly preclinical, with only a handful of small human reports and no rigorous randomized trials. Natural thymosin beta-4 has more human research — including eye-surface trials — than the synthetic TB-500 fragment specifically. Neither compound is FDA approved, both are sold as research chemicals with unverified purity, and both are prohibited in tested sports.
Frequently asked questions
Should I use BPC-157 or TB-500 for an injury?
There is not enough human evidence to say either works for a given injury. Both are mostly supported by animal studies. A sports-medicine physician or physical therapist is the right starting point for an injury.
Can BPC-157 and TB-500 be stacked?
They are commonly combined on the theory that their mechanisms are complementary, but no human trials have tested the combination.
Are BPC-157 and TB-500 banned in sports?
Yes. Both appear on the World Anti-Doping Agency’s prohibited list, so athletes in tested sports should avoid them.
Sources
- Vasireddi N et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. PMID 40756949.
- Chang CH et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. PMID 21030672.
- Hannappel E (2007). beta-Thymosins. Ann N Y Acad Sci. PMID 17468232.
- Mendias CL, Awan TM (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. PMID 41966639.
For informational and research purposes only — not medical advice. Talk to a licensed clinician before starting, stopping, or combining any of these compounds. See our Terms.